Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01672866 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT01672866 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 222 participants.
The verdict
NCT01672866, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants with NASH. It will consist of 2 phases: * Randomized Double-Blind Phase * Open-Label Phase (optional)
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL SIM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2012-12-05 |
| Est. Completion | 2016-12-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01672866
The ClinicalTrials.gov registry entry for NCT01672866 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01672866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01672866 about?
NCT01672866 is a clinical study titled "Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)". The primary objective of this study is to evaluate whether SIM (formerly referred to as GS-6624) is effective at preventing the histologic progression of liver fibrosis and the clinical progression to cirrhosis in participants with NASH. It will consist of 2 phases: * Randomized Double-Blind Phase...
What is the current status of trial NCT01672866?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2012-12-05. Estimated completion is 2016-12-29.
What interventions are being tested in trial NCT01672866?
The interventions under investigation include: Placebo (BIOLOGICAL), SIM (BIOLOGICAL).
Who is sponsoring clinical trial NCT01672866?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.